Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood spies new frontier for $1B drug in exploratory trial
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
Ironwood`s bowel disease drug meets main goal of late-stage study
Ironwood Announces Positive Results from Phase III of Once-Weekly Apraglutide
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results
Ironwood to Host Fourth Quarter and Full Year 2023 Investor Update Call
Ironwood Announces Publication of Linaclotide Phase III Data
Ironwood to Present at the 42nd Annual J.P. Morgan Healthcare Conference